BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) successfully developing, manufacturing, and releasing GMP drug product for use in clinical trials since 2022. With industry-recognized leadership, scientists, engineers, analysts, and manufacturing specialists, along with established quality systems and modern infrastructure, BioCentriq is a trusted strategic partner for the development and manufacture of both autologous and allogeneic cell therapies. In June 2023, BioCentriq launched its LEAP Advanced Therapy Platform designed to help cell therapy developers move from contract to clinic in as little as six months. The company was purchased by GC Holdings Inc. of South Korea for $73 million in May 2022.